TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18662491

Group type: EXPERIMENTAL
Intervention: TPB-based intervention with persuasive messages designed to change beliefs
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 300
Study: 16430721

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 15333404

Group type: COMPARATOR
Intervention: Rocuronium 10 mg/mL
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Rocuronium 1 mg/mL
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.5 mg/mL
Number of subjects: 150
Study: 11187176

Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heavy regular training
Number of subjects: 0
Study: 9352760

Group type: EXPERIMENTAL
Intervention: Siemens Servo 900C ventilator at CPAP level of 0.5 kPa
Number of subjects: 13

Group type: COMPARATOR
Intervention: Continuous flow CPAP (CF-CPAP) at CPAP level of 0.5 kPa
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Siemens Servo 900C ventilator
Number of subjects: 13
Study: 8470632

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg four times daily
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg four times daily
Number of subjects: 328

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328
Study: 3780291

Group type: EXPERIMENTAL
Intervention: Pinaverium bromide 100 mg twice daily for 3 days before and 100 mg 1 hour before examination
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: COMPARATOR
Intervention: No medication
Number of subjects: 18
Study: 29975092

Group type: EXPERIMENTAL
Intervention: Extensive training in two versions of an avoidance learning task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extensive training in an appetitive slips-of-action task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two independent attempts to replicate the original demonstration
Number of subjects: 0
Study: 27721231

Group type: EXPERIMENTAL
Intervention: Cold dialysis solution at 35.5°C
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional dialysis solution at 37°C
Number of subjects: 46
Study: 25153486

Group type: EXPERIMENTAL
Intervention: Corticosteroids (CS) alone
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Add-on therapies (cytotoxic agents, biotherapies, intravenous immunoglobulins, and plasma exchanges)
Number of subjects: 193
Study: 22695364

Group type: EXPERIMENTAL
Intervention: Isoniazid (INH) 10-20 mg·kg·d orally
Number of subjects: 151
Study: 20512350

Group type: EXPERIMENTAL
Intervention: Complete PANP + LLND surgery combined with intraoperative radiotherapy (preserved group)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Pelvic autonomic nerve resection + LLND surgery (resected group)
Number of subjects: 55
Study: 18719669

Group type: EXPERIMENTAL
Intervention: Endurance exercise training for 12 weeks
Number of subjects: 41
Study: 15972865

Group type: EXPERIMENTAL
Intervention: Vinorelbine plus cisplatin
Number of subjects: 482

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 482
Study: 10522354

Group type: EXPERIMENTAL
Intervention: Ultrasound (US)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 32
Study: 8747374

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4-hydroxyphenylretinamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tamoxifen and 4-hydroxyphenylretinamide
Number of subjects: 0
Study: 2196926

Group type: EXPERIMENTAL
Intervention: 1% hydrocortisone cream
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of 1% hydrocortisone cream and 2% miconazole cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrocortisone alone
Number of subjects: 0
Study: 6101961

Group type: EXPERIMENTAL
Intervention: Pirbuterol 10 mg four times daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Salbutamol 4 mg four times daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 0
Study: 30010773

Group type: EXPERIMENTAL
Intervention: Tdap
Number of subjects: 273

Group type: COMPARATOR
Intervention: Td
Number of subjects: 273
Study: 26940987

Group type: EXPERIMENTAL
Intervention: Therapeutic Hypothermia (33.0°C)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Normothermia (36.8°C)
Number of subjects: 87
Study: 24567515

Group type: EXPERIMENTAL
Intervention: BMI categories in DLBCL patients
Number of subjects: 1549

Group type: EXPERIMENTAL
Intervention: BMI categories in HL patients
Number of subjects: 1549

Group type: EXPERIMENTAL
Intervention: BMI categories in FL patients
Number of subjects: 1549

Group type: EXPERIMENTAL
Intervention: R-CHOP treatment in males with DLBCL
Number of subjects: 1549
Study: 22700717

Group type: EXPERIMENTAL
Intervention: Simvastatin + Ezetimibe (S + E)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Simvastatin (S)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Lipid-lowering treatment (LLT)
Number of subjects: 39
Study: 19962941

Group type: EXPERIMENTAL
Intervention: Pramipexole (0.125 to 0.75 mg/day for 6 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17377856

Group type: EXPERIMENTAL
Intervention: Direct autologous retransfusion of shed thoracic blood (350 ml)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (350 ml saline)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Direct autologous retransfusion of shed thoracic blood
Number of subjects: 44
Study: 16352934

Group type: EXPERIMENTAL
Intervention: 0.3 mg of ramosetron (RAM) combined with 8 mg of dexamethasone (DEX)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 0.3 mg of ramosetron (RAM) combined with 12 mg of dexamethasone (DEX)
Number of subjects: 25
Study: 12171817

Group type: EXPERIMENTAL
Intervention: Oxygen inhalation at 2 L/min
Number of subjects: 75
Study: 9832489

Group type: EXPERIMENTAL
Intervention: Plasma BNP levels in ARVD patients
Number of subjects: 149

Group type: COMPARATOR
Intervention: Plasma BNP levels in RVOT patients
Number of subjects: 149

Group type: COMPARATOR
Intervention: Plasma BNP levels in control subjects
Number of subjects: 149
Study: 8088143

Group type: EXPERIMENTAL
Intervention: Softened fabrics
Number of subjects: 15

Group type: COMPARATOR
Intervention: Unsoftened fabrics
Number of subjects: 15
Study: 2732867

Group type: EXPERIMENTAL
Intervention: Rice-based ORS
Number of subjects: 93

Group type: COMPARATOR
Intervention: Glucose ORS
Number of subjects: 93
Study: 30099811

Group type: EXPERIMENTAL
Intervention: Losartan 5% ointment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 30
Study: 27661023

Group type: EXPERIMENTAL
Intervention: Cordimax (abluminal biodegradable polymer SES)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Cypher Select (durable polymer SES)
Number of subjects: 402
Study: 24411819

Group type: EXPERIMENTAL
Intervention: Family‐Centered Advance Care Planning for Teens With Cancer (FACE‐TC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 22128789

Group type: EXPERIMENTAL
Intervention: Hydrogel with MTC‐2G
Number of subjects: 41

Group type: COMPARATOR
Intervention: Hydrogel alone
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Comparison between groups
Number of subjects: 41
Study: 21293742

Group type: EXPERIMENTAL
Intervention: 400 mg of vitamin C daily
Number of subjects: 384

Group type: COMPARATOR
Intervention: Control group (no vitamin C supplementation)
Number of subjects: 384
Study: 18547452

Group type: EXPERIMENTAL
Intervention: MCHW intervention
Number of subjects: 5240
Study: 16036167

Group type: EXPERIMENTAL
Intervention: Ginger capsule
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Bottle filled with ginger capsules
Number of subjects: 80

Group type: COMPARATOR
Intervention: Bottle filled with placebo capsules
Number of subjects: 80
Study: 12203743

Group type: EXPERIMENTAL
Intervention: Personal relationship with the specialist (trust, care, understanding, respect, time given, being listened to, openness and honesty)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Risk of recurrence, life expectancy, side-effects, quality of life
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Further treatment to reduce risk
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Minor variations in treatment protocol
Number of subjects: 20
Study: 9066931

Group type: EXPERIMENTAL
Intervention: Revised Winter-Tozer equation
Number of subjects: 104

Group type: COMPARATOR
Intervention: Winter-Tozer equation (original)
Number of subjects: 104
Study: 1785672

Group type: EXPERIMENTAL
Intervention: MOPP + Bleo
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: A‐COPP
Number of subjects: 84
Study: 6803278

Group type: EXPERIMENTAL
Intervention: L-tryptophan (5 g)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pyridoxine (125 mg three times daily with meals) and L-tryptophan (3 g at 10 PM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maprotiline (100 mg at 10 PM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30735922

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Antipsychotic switch during the 8-week acute phase
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Higher positive symptoms at the endpoint
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Higher CGI-S score at the endpoint
Number of subjects: 569
Study: 29066452

Group type: EXPERIMENTAL
Intervention: Darapladib
Number of subjects: 15828
Study: 26498430

Group type: EXPERIMENTAL
Intervention: Synchronous whole-body vibrations (WBV) at 40 Hz, 4 mm for 60s and 90s
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group performing similar exercises without vibrations
Number of subjects: 36
Study: 25058216

Group type: EXPERIMENTAL
Intervention: Erythropoietin (500 IU/kg per dose)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Hemoglobin transfusion threshold of 7 g/dL
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Hemoglobin transfusion threshold of 10 g/dL
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Transfusion threshold of 10 g/dL
Number of subjects: 200
Study: 22733316

Group type: EXPERIMENTAL
Intervention: ICSI
Number of subjects: 441

Group type: COMPARATOR
Intervention: IVF
Number of subjects: 441
Study: 19777213

Group type: EXPERIMENTAL
Intervention: 200 mg BZP
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 17580150

Group type: EXPERIMENTAL
Intervention: Sirolimus conversion treatment (RAPA)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Cyclosporine (CsA) reduction
Number of subjects: 110
Study: 15446319

Group type: EXPERIMENTAL
Intervention: Basiliximab
Number of subjects: 105

Group type: COMPARATOR
Intervention: ATG
Number of subjects: 105
Study: 11475846

Group type: EXPERIMENTAL
Intervention: Ultrasound skin measurement
Number of subjects: 103
Study: 10817004

Group type: EXPERIMENTAL
Intervention: Morphine (at a dilution of 1 mg/ml)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Tramadol (at a dilution of 10 mg/ml)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 88

Group type: COMPARATOR
Intervention: Tramadol
Number of subjects: 88

Group type: COMPARATOR
Intervention: Both Morphine and Tramadol
Number of subjects: 88
Study: 7602396

Group type: EXPERIMENTAL
Intervention: Cemented fixation
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Uncemented fixation
Number of subjects: 33

Group type: COMPARATOR
Intervention: Cemented and uncemented fixation
Number of subjects: 33
Study: 2182447

Group type: EXPERIMENTAL
Intervention: 50 mg daily oral fluconazole
Number of subjects: 248

Group type: COMPARATOR
Intervention: Oral polyenes (control)
Number of subjects: 248
Study: 391753

Group type: EXPERIMENTAL
Intervention: Pemoline 50 mg daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31986899

Group type: EXPERIMENTAL
Intervention: Intervention group (received additional home visit with health education materials in English and Navajo)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (received standard care with one home visit discussing mammography pros/cons and barriers)
Number of subjects: 25
Study: 31567567

Group type: EXPERIMENTAL
Intervention: T2Candida
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum BDG and T2Candida
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BDG-guided empiric antifungal treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCR
Number of subjects: 0
Study: 27439324

Group type: EXPERIMENTAL
Intervention: Tomosynthesis
Number of subjects: 158

Group type: COMPARATOR
Intervention: DE imaging
Number of subjects: 158

Group type: COMPARATOR
Intervention: Conventional chest radiography
Number of subjects: 158
Study: 26525422

Group type: EXPERIMENTAL
Intervention: Bath emollients plus standard eczema care
Number of subjects: 423

Group type: COMPARATOR
Intervention: Standard eczema care only
Number of subjects: 423
Study: 24229749

Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (72 mg/d)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study: 21561398

Group type: EXPERIMENTAL
Intervention: Memantine plus rivastigmine patch
Number of subjects: 172

Group type: COMPARATOR
Intervention: Rivastigmine patch monotherapy
Number of subjects: 172
Study: 19321287

Group type: EXPERIMENTAL
Intervention: CD-ROM intervention group
Number of subjects: 48
Study: 17688463

Group type: EXPERIMENTAL
Intervention: Long-acting injectable risperidone (LAI-ris)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Oral atypical antipsychotic (AAP)
Number of subjects: 49
Study: 15507939

Group type: EXPERIMENTAL
Intervention: Single-dose parecoxib sodium 40 mg
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Multiple-dose parecoxib sodium 20 mg, 4 times daily
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Multiple-dose parecoxib sodium 40 mg, twice daily
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208

Group type: COMPARATOR
Intervention: Morphine 4 mg
Number of subjects: 208

Group type: COMPARATOR
Intervention: Ketorolac 30 mg
Number of subjects: 208
Study: 11514692

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 236
Study: 9596002

Group type: EXPERIMENTAL
Intervention: Major neurologic complications (metabolic encephalopathy, seizures, psychiatric symptoms, cerebral hemorrhage, cerebral abscess, leukemic meningitis, peripheral neuropathies, myopathies)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Minor neurologic complications (headache, tremor)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Metabolic encephalopathy
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Survival at day 90
Number of subjects: 115
Study: 9609369

Group type: EXPERIMENTAL
Intervention: Tetracycline
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 2666759

Group type: EXPERIMENTAL
Intervention: Desmopressin acetate (0.3 microgram/kg intravenously over 15 minutes at the conclusion of cardiac bypass)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Desmopressin acetate
Number of subjects: 60
Study: 791437

Group type: EXPERIMENTAL
Intervention: Synthetic absorbable polyglactin suture
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Synthetic absorbable polyglycolic acid suture
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Non-absorbable polypropylene suture
Number of subjects: 161

Group type: COMPARATOR
Intervention: Surgeons in training
Number of subjects: 161
Study: 31721249

Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Lower UNa (≤60 mmol/L)
Number of subjects: 360
Study: 31462203

Group type: EXPERIMENTAL
Intervention: Standard initiation of renal replacement therapy
Number of subjects: 2866

Group type: COMPARATOR
Intervention: Accelerated initiation of renal replacement therapy
Number of subjects: 2866
Study: 28035867

Group type: EXPERIMENTAL
Intervention: SC golimumab 50 mg every 4 weeks through week 12, continued for good responders through week 52 (Group 1)
Number of subjects: 433

Group type: COMPARATOR
Intervention: SC golimumab 50 mg (Group 2-SC)
Number of subjects: 433

Group type: COMPARATOR
Intervention: IV golimumab 2 mg/kg (Group 2-IV)
Number of subjects: 433

Group type: COMPARATOR
Intervention: SC golimumab and IV golimumab (Groups 2-SC and 2-IV)
Number of subjects: 433

Group type: COMPARATOR
Intervention: SC golimumab and IV golimumab
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Overall trial population
Number of subjects: 433
Study: 24867603

Group type: EXPERIMENTAL
Intervention: High dose (HD, 6 mg.kg(‐1))
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Medium dose (MD, 4 mg.kg(‐1))
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low dose (LD, 2 mg.kg(‐1))
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 12
Study: 23230069

Group type: EXPERIMENTAL
Intervention: Endotracheal tube with stylet
Number of subjects: 232

Group type: COMPARATOR
Intervention: Endotracheal tube without stylet
Number of subjects: 232
Study: 21311871

Group type: EXPERIMENTAL
Intervention: Written materials
Number of subjects: 1174

Group type: EXPERIMENTAL
Intervention: Videocassette and written materials
Number of subjects: 1174

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1174
Study: 19170120

Group type: EXPERIMENTAL
Intervention: Process-then-suppress
Number of subjects: 59

Group type: COMPARATOR
Intervention: Suppress-then-process
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Approach-avoidance coping conflict
Number of subjects: 59
Study: 16946696

Group type: EXPERIMENTAL
Intervention: Lamotrigine monotherapy (100-200 mg/day)
Number of subjects: 1127

Group type: EXPERIMENTAL
Intervention: Lamotrigine monotherapy with ASH as supplemental medication
Number of subjects: 1127

Group type: EXPERIMENTAL
Intervention: Lamotrigine monotherapy with ASH vs other psychotropic medications
Number of subjects: 1127

Group type: EXPERIMENTAL
Intervention: Lamotrigine adjunctive therapy with ASH
Number of subjects: 1127
Study: 15468370

Group type: EXPERIMENTAL
Intervention: Higher serum levels of TNF‐sR1
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Higher serum levels of TNF‐sR2
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Higher serum levels of TNF‐sR1 and TNF‐sR2
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Higher serum levels of IL‐6
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: CRP, IL‐6sR, IL‐2sR
Number of subjects: 274
Study: 11308436

Group type: EXPERIMENTAL
Intervention: Use of the CONSORT statement (post-1994)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Reports from journals that did not adopt CONSORT (control group)
Number of subjects: 211
Study: 9220226

Group type: EXPERIMENTAL
Intervention: Mesigyna
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: TriNovum
Number of subjects: 60
Study: 7955822

Group type: EXPERIMENTAL
Intervention: Caffeine-containing analgesic (APAP/ASA/CAF: 500 mg acetaminophen, 500 mg aspirin, 130 mg caffeine)
Number of subjects: 2811

Group type: EXPERIMENTAL
Intervention: Caffeine-containing analgesic (APAP/CAF: 1000 mg acetaminophen, 130 mg caffeine)
Number of subjects: 2811

Group type: COMPARATOR
Intervention: 1000 mg acetaminophen
Number of subjects: 2811

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2811
Study: 3211484

Group type: EXPERIMENTAL
Intervention: 1.0 mg/ml mitomycin eye drops
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 0.4 mg/ml mitomycin eye drops
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo eye drops
Number of subjects: 44
Study: 31673103

Group type: EXPERIMENTAL
Intervention: Trastuzumab for HER2 + EBC (12 months treatment, defined as ≥350 days of exposure within 540 days of initiation)
Number of subjects: 14644

Group type: EXPERIMENTAL
Intervention: Trastuzumab for HER2 + EBC
Number of subjects: 14644

Group type: EXPERIMENTAL
Intervention: Trastuzumab for HER2 + EBC (≥12 months treatment)
Number of subjects: 14644
Study: 27780692

Group type: EXPERIMENTAL
Intervention: High protein diet combined with weight-loss cognitive behavioral therapy
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: High carbohydrate diet combined with weight-loss cognitive behavioral therapy
Number of subjects: 88

Group type: COMPARATOR
Intervention: Both groups pooled (high protein and high carbohydrate)
Number of subjects: 88
Study: 25394396

Group type: EXPERIMENTAL
Intervention: Cognitive-motor dual-task using auditory cues
Number of subjects: 37

Group type: COMPARATOR
Intervention: Single-task group (treadmill walking only)
Number of subjects: 37
Study: 23410541

Group type: EXPERIMENTAL
Intervention: Angina (A)
Number of subjects: 2364

Group type: EXPERIMENTAL
Intervention: Angina equivalents (E)
Number of subjects: 2364

Group type: COMPARATOR
Intervention: Neither angina nor angina equivalents (N)
Number of subjects: 2364
Study: 21697075

Group type: EXPERIMENTAL
Intervention: 300 IU/d from fortified ultra-high-temperature pasteurized milk from the United States
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: 300 IU/d from fortified pasteurized Mongolian milk
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: 300 IU/d from supplements
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: a one-time seasonal supplement of 13,700 IU
Number of subjects: 579

Group type: COMPARATOR
Intervention: unfortified pasteurized Mongolian milk
Number of subjects: 579